| Literature DB >> 35530943 |
Ying Zhang1,2, Yuan Tang1, Jing Huang3, Huang Liu2,4, Xiaohua Liu2,4, Yu Zhou2,4, Chunjie Ma2,4, Qiling Wang2,4, Jigao Yang3, Fei Sun1, Xinzong Zhang2,4.
Abstract
Background: Because of focal spermatogenesis in some nonobstructive azoospermia (NOA) patients, testicular spermatozoa can be retrieved by microdissection testicular sperm extraction (micro-TESE) for intracytoplasmic sperm injection (ICSI) to achieve successful fertilization. Currently, testicular biopsy is widely performed for the prognosis of micro-TESE; however, it might miss foci with active spermatogenesis because of the 'blind manner' of puncture, highlighting the needs for biomarkers that could indicate actual spermatogenesis conditions in the testis. Thus, we screened microRNAs in the seminal plasma for potential biomarkers to provide a non-invasive and reliable preoperative assessment for micro-TESE.Entities:
Keywords: Nonobstructive azoospermia; biomarker; microRNA; microdissection testicular sperm extraction (micro-TESE); spermatogenesis
Year: 2022 PMID: 35530943 PMCID: PMC9073789 DOI: 10.21037/atm-21-5100
Source DB: PubMed Journal: Ann Transl Med ISSN: 2305-5839
Figure 1Study design. Flow diagram of the study. RT-qPCR, reverse transcription-quantitative polymerase chain reaction; UMI, unique molecular index; sRNA-seq, small RNA sequencing.
Baseline characteristics of enrolled NOA patients
| Characteristics (mean ± SD) | Fair group (n=48) | Poor group (n=68) |
|---|---|---|
| Male age (years) | 30±4 | 31±5 |
| Female partner age (years) | 28±5 | 28±4 |
| Infertile duration (years) | 4±2 | 4±2 |
| Testicular volume (mL) | 14±3* | 12±5* |
| Serum FSH (IU/L) | 15.33±8.01* | 15.75±8.12* |
| Serum LH (IU/L) | 7.02±5.05* | 7.87±5.73* |
*, no significant difference, Student’s t-test. NOA, nonobstructive azoospermia; FSH, follicle-stimulating hormone; LH, luteinizing hormone.
Figure 2Selection of differentially expressed microRNAs from sRNA-seq. (A) A total of 489 microRNAs were identified as differentially expressed microRNAs among 18 samples. (B) Intergroup analysis identified 80 differentially expressed microRNAs among the good, fair and poor groups; sRNA-seq, small RNA sequencing.
Figure 3Expression patterns of the selected microRNAs in the three groups. Four patterns were identified based on the expression level changes from the “good” group to the “poor” group.
Figure 4Selection of potential predictors by RT-qPCR. Expression profile of the 12 selected microRNAs in the different groups. RT-qPCR data of the 12 selected microRNAs showed the relative expression levels in the “good”, “fair” and “poor” groups. Among these 12 microRNAs, miR-34b-3p and miR-34c-3p were significantly downregulated from the “good” group to the “poor” group, and miR-4446-3p and miR-3065-3p were significantly upregulated from the “good” group to the “poor” group. (***P<0.001, **P<0.01, *P<0.05). RT-qPCR, reverse transcription-quantitative polymerase chain reaction.
The predictive formula model for micro-TESE
| Variable | Value | Std.Error | t value |
|---|---|---|---|
| Coefficients | |||
| hsa.miR.34b.3p | 0.13448 | 0.3400 | 0.3956 |
| hsa.miR.34c.3p | 0.58679 | 0.3704 | 1.5843 |
| hsa.miR.3065.3p | 0.15636 | 0.4112 | 0.3802 |
| hsa.miR.4446.3p | 0.09523 | 0.3542 | 0.2688 |
| Intercepts | |||
| G|F† | 2.0881 | 2.7436 | 0.7611 |
| F|P‡ | 3.0533 | 2.7656 | 1.1040 |
polr(formula = as.ordered(result) − hsa.miR.34b.3p + hsa.miR.34c.3p + hsa.miR.3065.3p + hsa.miR.4446.3p). †, Logit(Pg) = 2.0881 + 0.13448 hsa.miR.34b.3p + 0.58679 hsa.miR.34c.3p + 0.15636 hsa.miR.3065.3p + 0.09523 hsa.miR.4446.3p. ‡, Logit(Pg + Pf) = 3.0533 + 0.13448 has.miR.34b.3p + 0.58679 hsa.miR.34c.3p + 0.15636 hsa.miR.3065.3p + 0.09523 hsa.miR.4446.3p. Pp = 1 − Pg-Pf. micro-TESE, microdissection testicular sperm extraction.
Predictive model output
| Predictive result | Good | Fair | Poor | Total |
|---|---|---|---|---|
| Good | 6 | 2 | 0 | 8 |
| Fair | 0 | 8 | 1 | 9 |
| Poor | 0 | 2 | 21 | 23 |
| Total | 6 | 12 | 22 | – |
| Accuracy | 100% | 66.67% | 95.45% | – |
Predictive model evaluation
| Predictive result | Clinical result | ||
|---|---|---|---|
| Positive (+) | Negative (−) | Total | |
| Positive (+) | 16 | 2 | 18 |
| Negative (−) | 1 | 21 | 22 |
| Total | 17 | 23 | – |
Predictive result: FPR 8.70%; FNR 5.88%; TPR 88.89%; TNR 95.45%. Clinical result: sensitivity 94.12%; specificity 91.30%. FPR, false positive rate; FNR, false negative rate; TPR, true positive rate; TNR, true negative rate.
Figure 5ROC curve analysis for the performance of the predictive model. (A) ROC curve for the predictive model discriminating the “success” group from the “fair” group, AUC 0.927; (B) ROC curve for the predictive model discriminating the “good” group from the “poor” group, AUC 0.955; (C) ROC curve for the predictive model discriminating the “fair” group from the “poor” group, AUC 0.913; (D) ROC curve for the predictive model discriminating the “good” group from the “fair” group, AUC 0.707. AUC, area under the curve. 0.5< AUC <1 indicates for good predictive value. ROC, receiver operating characteristic; AUC, area under the curve.